LYB · Q2 2025 Earnings
CautiousLyondellBasell
Reported August 1, 2025
30-second summary
Revenue fell 11.8% YoY to $7.66B and EBITDA ex-items came in at $715M as the petrochemical trough deepened. The headline isn't the print — it's the pivot: LYB deferred construction of Flex-2, postponed the final investment decision on MoreTec2 (FEED continues through year-end 2025), cut 2025 capex by $100M to $1.7B ($200M total reduction vs. original 2025 guide), cut 2026 capex by another $300M to $1.4B, and explicitly took share buybacks off the table for 2025-2026. Management is now playing defense to protect the dividend and investment-grade rating through an extended downcycle.
Headline numbers
EPS
Q2 FY2025
$0.62
Revenue
Q2 FY2025
$7.66B
-11.8% YoY
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $7.66B | -11.8% |
| EPS | $0.62 | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| EBITDA (excluding identified items) | $715 million |
| North American Olefins & Polyolefins Operating Rate (Q3 Expected) | 85% |
| European Olefins & Polyolefins Operating Rate (Q3 Expected) | 75% |
| Intermediates & Derivatives Operating Rate (Q3 Expected) | 80% |
| Cash from Operating Activities | $351 million |
| Cash Improvement Plan Run-Rate Target 2025 | $600 million |
| Total Liquidity | $6.354 billion |
| Shareholder Returns (Dividends & Repurchases) | $536 million |
Management tone
Management's posture this quarter is materially more defensive than LYB's typical communications. The shift is from growth-capital deployment to cash hoarding, framed around protecting the dividend and the investment-grade rating.
Capex framework flipped from "deploy" to "defer." LYB deferred construction of Flex-2 and postponed the final investment decision on MoreTec2 (front-end engineering and design continues through year-end 2025), alongside a $100M cut to 2025 capex ($1.7B, a cumulative $200M reduction from the original 2025 guide) and a further $300M cut to 2026 ($1.4B). From the call: "We will reassess timing once market conditions inevitably improve, preserving this real option for profitable growth." The word "inevitably" is doing heavy lifting — it signals confidence that the cycle turns, while implying the turn is far enough out to justify pulling forward roughly $500M of capex relief.
Capital returns reframed as a defensive priority, not a confidence signal. Buybacks are off the table for 2025 AND 2026; only the dividend remains. Per Q&A with Fermium: Q3 dividend held at $1.37/share, $6.35B liquidity, $1.4B minimum cash target. The message: the dividend is safe because everything else has been cut to protect it — not because cash generation supports it.
European footprint reframed from platform to portfolio exit. Management announced the proposed sale of four European O&P assets in June, describing the strategy as "right-sizing our European asset base." This is a structural admission that European cracker economics are not recoverable at any reasonable cycle midpoint.
Demand commentary downshifted to risk-monitoring language. From the call: "We're closely monitoring evolving tariffs and global trade flows... we remain watchful for the potential effects of volatile trade policies." "Cautiously optimistic" on China stimulus is doing similar hedging work. This is vigilance language, not operational confidence.
Mid-cycle EBITDA potential characterized as delayed, not impaired. Per Wells Fargo Q&A: management views the downturn as cyclical with eventual rebound, not a structural reset of earnings power. Whether that holds depends on how long "inevitably" actually means.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Frank Mitch · Fermium Research
Given extended chemical downturn and other companies cutting dividends, what are management's thoughts on dividend safety at Liondell given weak operating cash flow relative to shareholder returns?
Management confirmed Q3 dividend of $1.37/share consistent with Q2, reaffirmed commitment to investment grade rating as capital allocation foundation, started 2025 with $3.4B cash, maintain $1.4B minimum cash balance with $6.35B total liquidity, no further buybacks planned for 2025-2026, and $1.1B cash improvement plan on track. Emphasized confidence in cycle rebound and emerging stronger.
Vincent Andrews · Morgan Stanley
Clarification on whether 2026 capex forecast of $1.4B includes $110M reduction from European asset sale; and sizing of precious metals opportunity benefits from new VAM technology.
2026 capex of $1.4B is on existing base; $110M reduction from European asset will be reflected post-transaction close. VAM transitioning to silica-based catalyst with three reactors at La Porte unit starting end of 2025, with transition continuing through 2028—no material 2026 impact. Q2 precious metals sales were $35M.
Jeff Sikoski · JPMorgan
Cash flow from operations declined from $1.2B in H1 2024 to deficit of ~$230M in H1 2025; what is expected cash flow generation for full 2025 and what factors are driving the decline?
Q1 2025 was negative due to working capital build and Hurricane Beryl tax payments ($579M deficit). Q2 was positive at $359M ($930M swing). H2 typically stronger (H2 2024 was 167% conversion, Q4 alone 280%). Targeting 80% full-year cash conversion with expected positive H2 cash flow from operations. Working capital discipline and fixed cost reductions will support recovery.
Michael Sisson · Wells Fargo
Given mixed signals (polyethylene price momentum offset by OxyFuel challenges), will earnings be up or down in Q3; and has mid-cycle EBITDA potential changed or just delayed?
Q3 expected improvements: $85M from less ONP Americas downtime (Channelview turnarounds), improved polyethylene margins from price increases, cash improvement plan fixed cost reductions across portfolio. O&P resilient with strong exports and changing consumer behavior supporting packaging. IND margins not expected to improve; Acetyls turnaround in La Porte mid-September. Mid-cycle potential viewed as delayed, not diminished, given difficult trough and expectation of eventual cycle rebound.
Kevin McCarthy · Vertical Research Partners
Third quarter dynamics in intermediates and derivatives segment: had nice Q2 improvement but commentary on MTB and styrene suggests caution; expect sequential step-down and how does this fit cycle view?
Q1-Q2 improvement included one-time PO11 JV exit costs. Q3 outlook: no material margin improvements expected. PON customers quoting 10%+ year-over-year declines. Acetyls turnaround mid-September affects Q3-Q4. Channelview methanol unit (down Q2) expected back up, offsetting La Porte turnaround impact. OxyFuels oversupplied; POTBA running above benchmark; Chinese volume displacing U.S. Gulf Coast volume. Q3 vs Q2 expected relatively flat.
What to watch into next quarter
H2 2025 operating cash flow recovery against the 80% full-year conversion target. With H1 at roughly -$230M, hitting 80% conversion requires H2 generation in the range of $3B+ — a steep ask that hinges on working capital release and the $600M cash improvement run-rate landing on schedule.
Q3 N.A. polyethylene margin expansion. Management explicitly cited June price increases and completed Channelview turnarounds as the $85M Q3 swing factor. If polyethylene margins don't expand sequentially in Q3, the cyclical-recovery framing weakens.
European asset sale closure timing and proceeds. The announced sale of four European O&P assets carries a $110M capex reduction post-close and is the most concrete portfolio action; delays or repricing would signal that European exit economics are worse than implied.
Dividend coverage trajectory. Trailing-12-month shareholder returns of $2.1B against H1 negative operating cash flow is unsustainable on a sustained basis. Watch whether Q3 cash from operations covers the quarterly dividend (~$445M) plus sustaining capex.
Whether any further capex or project deferrals are announced. Flex-2 construction is deferred and MoreTec2 FID is postponed. A third deferral would signal management views the cycle trough as deeper or longer than even today's defensive posture implies.
Sources
- LyondellBasell Q2 2025 press release, SEC filing — https://www.sec.gov/Archives/edgar/data/1489393/000148939325000038/a2025q2ex991_pressrelease.htm
- LyondellBasell Q2 2025 earnings call prepared remarks and Q&A
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.